2026-01-04 - Analysis Report
Okay, here's a comprehensive report on Teladoc Health Inc (TDOC), incorporating all the data you provided.

**1) Return Rate Comparison with S&P 500 (VOO)**

*   **Ticker:** TDOC
*   **Company Name:** Teladoc Health Inc
*   **Company Overview:** Teladoc Health is a telehealth company providing virtual healthcare services.
*   **TDOC Cumulative Return:** -64.46%
*   **VOO Cumulative Return:** 91.00%
*   **Divergence:**
    *   Maximum: 305.8
    *   Minimum: -158.7
    *   Current: -156.6
    *   Relative Divergence: 0.5

**Analysis:**

*   TDOC has significantly underperformed the S&P 500 (VOO).  The cumulative return is drastically negative while VOO has achieved substantial gains.
*   The divergence shows the extreme difference in performance. The current divergence is near the *minimum* divergence value observed in the past, suggesting the underperformance is near its worst levels relative to VOO.  The relative divergence of 0.5 indicates the current underperformance is near the lower end of its historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR     | MDD  | Alpha     | Beta | Cap(B) |
|------------|----------|------|-----------|------|--------|
| 2016-2018  | 74.0%    | 52.9% | 71.0%     | 1.7  | 8.8    |
| 2017-2019  | 119.0%   | 52.9% | 101.0%    | 1.8  | 14.9   |
| 2018-2020  | 87.0%    | 52.9% | 66.0%     | 0.7  | 35.5   |
| 2019-2021  | -84.0%   | 60.6% | -127.0%   | 0.5  | 16.3   |
| 2020-2022  | -246.0%  | 83.0% | -244.0%   | 0.8  | 4.2    |
| 2021-2023  | -302.0%  | 83.0% | -303.0%   | 1.9  | 3.8    |
| 2022-2024  | -87.0%   | 72.3% | -107.0%   | 1.9  | 1.6    |
| 2023-2025  | -34.0%   | 65.6% | -96.0%    | 1.7  | 1.2    |

**Analysis:**

*   **CAGR:** The Compounded Annual Growth Rate is negative for the most recent periods, indicating a decline in investment value.
*   **MDD:**  The Maximum Drawdown shows significant downside risk, reaching over 80% in some periods.  This indicates periods of substantial loss.
*   **Alpha:**  The consistently negative Alpha for recent years suggests TDOC is significantly underperforming its benchmark *even after* accounting for market risk (Beta).
*   **Beta:** The Beta values fluctuate, but are generally above 1.0. This indicates TDOC's price tends to be more volatile than the overall market (S&P 500). A Beta of 1.9 in recent periods suggests a high degree of volatility relative to the market.
*   **Cap(B):** Market capitalization has dramatically shrunk from 8.8B to 1.2B over the time period shown.

**2) Recent Stock Price Fluctuations**

*   **Current Close:** 7.05
*   **Last-market:** Price = 7.05, Previous Close = 7.00, Change = 0.71
*   **5-day SMA:** 7.02
*   **20-day SMA:** 7.334
*   **60-day SMA:** 7.7648

**Analysis:**

*   The stock price is below all three Simple Moving Averages (SMAs), suggesting a possible downtrend.
*   The 5-day SMA is slightly below the current price, potentially indicating a very short-term upward blip.

**3) RSI, PPO, and Other Indicators**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment Recommended)
*   **RSI:** 27.56
*   **PPO:** -0.3152
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (133 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** 0.5 (+): 단기상승 (Short-term rise)
*   **Price Change Impact:**  A significant price change from previous close reflects the fluctuation issue (sharp rebound, sharp decline).
*   **Expected Return (%):** -9740.8
*   **Expected Excess Return:** Negative (compared to S&P 500)

**Analysis:**

*   **MRI:** A moderate risk.
*   **RSI:** The RSI is below 30, indicating *oversold* conditions.  This *could* suggest a potential buying opportunity, but should be considered in conjunction with other factors.
*   **PPO:** The negative PPO suggests the short-term moving average is below the long-term moving average, indicating a potential downtrend or weakening momentum.
*   **Hybrid Signal:** The signal suggests buying a significant amount of shares with available cash, indicating high confidence.
*   **Recent Divergence Change:**  A short-term increase in divergence could be a short term rise, but this may not be sustainable.
*   **Expected Return:** The extremely negative expected return suggests very poor projected performance compared to S&P 500 from this point forward.

**4) Recent News & Significant Events**

*   **[2025-12-13] Forget Teladoc and Buy This Healthcare Stock Instead (The Motley Fool):** Suggests alternatives to TDOC may be more promising.
*   **[2026-01-03] How the (TDOC) price action is used to our Advantage (TDOC:CA) (Stock Traders Daily):** Implies strategies to profit from TDOC's price movements, possibly indicating volatility or trading opportunities.
*   **[2025-12-22] Why Teladoc (TDOC) Stock Is Up Today (Yahoo Finance):** Explains a specific reason for a short-term price increase.
*   **[2025-12-24] HIMS vs. TDOC: Which Telehealth Stock Looks More Compelling? (Zacks Investment Research):**  Compares TDOC with a competitor, HIMS, implying potential concerns or a search for better investments.
*   **[2025-10-06] Teladoc (TDOC) Stock Drops Despite Market Gains: Important Facts to Note (Nasdaq):** Highlights underperformance relative to the broader market.
*   **[2025-12-20] Is Teladoc a Bargain After a 96% Slide and DCF Suggesting Major Upside? (simplywall.st):** Questions whether the large price decline has made TDOC undervalued, but suggests potential upside based on a Discounted Cash Flow (DCF) analysis.

**Analysis:**

*   The news headlines are mixed, but with a generally negative slant. Articles discussing alternatives to TDOC, underperformance, and price drops raise concerns. The article suggesting TDOC is a bargain highlights a potential upside, but this is balanced against the more pessimistic articles.

**4-2) Analyst Opinions**

*   **Analyst Consensus:**
    *   Key: None
    *   Mean (1=StrongBuy~5=Sell): - (~-)
    *   Opinions: 22
    *   Target Price (avg/high/low): 9.18 / 12.00 / 7.00

**Analysis:**

*   The average target price of $9.18 represents a potential upside from the current price of $7.05.  However, the low target price of $7.00 indicates some analysts believe the stock has limited or no upside.

**5) Recent Earnings Analysis**

| 날짜       | EPS   | 매출      |
|------------|-------|-----------|
| 2025-10-30 | -0.28 | 0.63 B$  |
| 2025-07-30 | -0.19 | 0.63 B$  |
| 2025-05-01 | -0.53 | 0.63 B$  |
| 2024-10-31 | -0.19 | 0.64 B$  |
| 2025-10-30 | -0.19 | 0.64 B$  |

**Analysis:**

*   **EPS (Earnings Per Share):** TDOC has reported negative EPS for all recent quarters, indicating unprofitability.
*   **Revenue:** Revenue has been relatively stable around $0.63-0.64 Billion. The limited revenue growth is not encouraging for a growth-oriented company.

**6) Financial Information:**

Revenue and Profitability:

| Quarter    | Revenue    | Profit Margin |
|------------|------------|----------------|
| 2025-09-30 | $0.63B     | 70.12%         |
| 2025-06-30 | $0.63B     | 69.85%         |
| 2025-03-31 | $0.63B     | 68.73%         |
| 2024-12-31 | $0.64B     | 70.50%         |
| 2024-09-30 | $0.64B     | 71.94%         |

Capital and Profitability:

| Quarter    | Equity     | ROE       |
|------------|------------|-----------|
| 2025-09-30 | $1.39B     | -3.56%    |
| 2025-06-30 | $1.42B     | -2.30%    |
| 2025-03-31 | $1.43B     | -6.52%    |
| 2024-12-31 | $1.49B     | -3.25%    |
| 2024-09-30 | $1.51B     | -2.21%    |

**Analysis:**

*   **Revenue:** As seen in the previous section, revenue is stagnant.
*   **Profit Margin:** While profit margins are high, they are not translating into overall profitability due to high operating costs.
*   **Equity:** Equity is decreasing, which is a negative sign, as it indicates that the company's assets are decreasing relative to its liabilities.
*   **ROE (Return on Equity):** Negative ROE confirms the company is not generating profits from shareholders' equity.

**7) Comprehensive Analysis (Summary)**

Teladoc Health (TDOC) presents a complex picture.

*   **Negative Performance:** The stock has significantly underperformed the S&P 500, with substantial negative cumulative returns and consistently negative Alpha in recent years.
*   **Financial Concerns:** The company is currently unprofitable, with negative EPS and ROE. Revenue growth is stagnant. Decreasing Equity.
*   **Technical Indicators:** The RSI suggests the stock may be oversold, but the downtrend indicated by the SMAs and PPO raise concerns.
*   **News Sentiment:** News articles are mixed but skew negative, highlighting concerns about underperformance and competition.
*   **Analyst Outlook:** Analyst opinions are mixed, with a potential upside based on average target prices, but limited upside or potential downside according to some analysts.
* **Hybrid Signal:** The indicator signals the potential to buy a significant amount of shares, indicating the potential for strong gains.
**Overall Assessment:**

While the oversold RSI and some analyst target prices suggest a potential for a rebound, the overall picture for TDOC is concerning. The company's unprofitability, negative performance relative to the market, and negative news sentiment outweigh any potential positive signals. A high level of caution is warranted. The recent divergence change and analyst recommendations to 'buy a significant amount of shares' seem optimistic, but must be taken in the context of the concerning indicators displayed.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.